Jolanda Howe Sells 57,606 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 57,606 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares of the company’s stock, valued at $214,698.35. This represents a 92.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 3rd, Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $51,306.08.
• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.

Mirum Pharmaceuticals Stock Up 6.4 %

Shares of NASDAQ MIRM opened at $47.13 on Thursday. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $54.23. The stock has a market cap of $2.31 billion, a PE ratio of -23.33 and a beta of 1.04. The business has a fifty day moving average of $47.65 and a two-hundred day moving average of $43.62. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIRM. GF Fund Management CO. LTD. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Mirum Pharmaceuticals by 16.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after acquiring an additional 10,427 shares in the last quarter. Woodline Partners LP increased its position in Mirum Pharmaceuticals by 22.2% in the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after acquiring an additional 73,399 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $897,000. Finally, Tema Etfs LLC acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $1,735,000.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MIRM. Robert W. Baird boosted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.